We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$717M
AUM Growth
+$143M
Cap. Flow
+$179M
Cap. Flow %
24.96%
Top 10 Hldgs %
42.64%
Holding
176
New
63
Increased
14
Reduced
29
Closed
31

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$15.9M
2
RCUS icon
Arcus Biosciences
RCUS
+$9.44M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.44M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$9.12M
5
BPMC
Blueprint Medicines
BPMC
+$8.44M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20.7M
2
SLNO
Soleno Therapeutics
SLNO
+$10.7M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.35M
4
NUVL
Nuvalent
NUVL
+$8.24M
5
AMGN icon
Amgen
AMGN
+$8.18M

Sector Composition

Rank Sector Weight
1 Healthcare 44.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
26
BridgeBio Pharma
BBIO
$16.4B
$7.27M 1.01%
285,613
-46,400
-14% -$1.22M
SRPT icon
27
Sarepta Therapeutics
SRPT
$1.64B
$6.77M 0.94%
54,176
-149,436
-73% -$20.7M
ONC
28
CALL
BeOne Medicines Ltd
ONC
$33.9B
$6.69M 0.93%
+29,800
New +$5.36M
CRBP icon
29
Corbus Pharmaceuticals
CRBP
$165M
$5.87M 0.82%
284,715
-24,825
-8% -$1.27M
NRIX icon
30
Nurix Therapeutics
NRIX
$2.45B
$5.84M 0.81%
260,000
-180,500
-41% -$4.09M
APLS
31
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$5.77M 0.8%
+200,000
New +$7.41M
AKRO
32
PUT
DELISTED
Akero Therapeutics
AKRO
$5.71M 0.8%
+198,900
New +$5.19M
SLNO
33
CALL
DELISTED
Soleno Therapeutics
SLNO
$5.55M 0.77%
+110,000
New +$5.27M
NUVL
34
DELISTED
Nuvalent
NUVL
$5.34M 0.75%
52,238
-99,363
-66% -$8.24M
NMRA icon
35
CALL
Neumora Therapeutics
NMRA
$306M
$5.28M 0.74%
+400,000
New +$4.67M
NMRA icon
36
PUT
Neumora Therapeutics
NMRA
$306M
$5.28M 0.74%
+400,000
New +$4.67M
ANRO icon
37
PUT
Alto Neuroscience
ANRO
$1.04B
$5.15M 0.72%
+450,000
New +$5.51M
GPCR icon
38
Structure Therapeutics
GPCR
$3.37B
$5.06M 0.71%
+115,200
New +$4.45M
MDGL icon
39
PUT
Madrigal Pharmaceuticals
MDGL
$12.6B
$4.99M 0.7%
+23,500
New +$6.01M
ANRO icon
40
CALL
Alto Neuroscience
ANRO
$1.04B
$4.93M 0.69%
+431,000
New +$5.27M
RLAY icon
41
Relay Therapeutics
RLAY
$4B
$4.91M 0.68%
+693,350
New +$5.18M
LENZ
42
LENZ Therapeutics
LENZ
$179M
$4.86M 0.68%
204,513
– –
CRBP icon
43
PUT
Corbus Pharmaceuticals
CRBP
$165M
$4.81M 0.67%
+233,100
New +$11.9M
DYN icon
44
PUT
Dyne Therapeutics
DYN
$4.68B
$4.78M 0.67%
+133,000
New +$5.29M
CAPR icon
45
CALL
Capricor Therapeutics
CAPR
$4.56M 0.64%
+300,000
New +$1.48M
CAPR icon
46
Capricor Therapeutics
CAPR
$4.56M 0.64%
+300,000
New +$1.48M
CAPR icon
47
PUT
Capricor Therapeutics
CAPR
$4.56M 0.64%
+300,000
New +$1.48M
VRDN icon
48
CALL
Viridian Therapeutics
VRDN
$2.2B
$4.55M 0.63%
200,000
+199,000
+19,900% +$3.25M
WVE icon
49
Wave Life Sciences
WVE
$1.12B
$4.46M 0.62%
544,265
-30,823
-5% -$184K
APLS
50
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$4.33M 0.6%
+150,000
New +$5.56M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ikarian Capital held 176 positions worth $717M, up 25% from $574M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $179M of net new capital in Q3 2024, opening 63 new positions and adding to 14 existing holdings. Its largest new stake was BeOne Medicines Ltd: 88,167 shares worth $1.64M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20.7M trimmed.

  • Ikarian Capital's largest Q3 2024 buy was BeOne Medicines Ltd: 88,167 shares worth $1.64M.
  • Ikarian Capital added most to Arcus Biosciences in Q3 2024, an estimated $9.44M increase.
  • Ikarian Capital's biggest Q3 2024 reduction was Sarepta Therapeutics, cutting an estimated $20.7M.
  • Ikarian Capital fully exited Immunovant in Q3 2024, selling an estimated $8.17M.
  • Ikarian Capital's ten largest holdings make up 43% of its $717M portfolio in Q3 2024.
  • Ikarian Capital opened 63 new positions and closed 31 in Q3 2024.
  • Ikarian Capital's portfolio value rose 25% quarter-over-quarter to $717M.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.